Conciseness

The body is dense with task-specific content Claude cannot reliably know from memory — exact parameter corrections ('param is uniprot_id (not id)', 'ensemblId (camelCase, not ensemblID)'), concrete thresholds (pLI > 0.9, LOEUF < 0.35, IC50 < 1μM, OpenTargets score > 0.7), and specific retry chains. Minor over-explanation exists ('LOOK UP, DON'T GUESS' is partly meta advice, and the Target Evaluation Reasoning Framework explains druggability concepts at length), but nearly every token is domain- or tool-specific rather than padding.

Actionability

Mostly concrete: a runnable get_tool_info code block, an executable GraphQL query example, per-path tool name lists, known parameter corrections, and explicit fallback chains ('ChEMBL_get_target_activities fails → GtoPdb_search_ligands → OpenTargets drugs'). The gap is that the detailed implementation code is delegated to IMPLEMENTATION.md, which is not present in the bundle, so per-path execution is directed rather than shown.

Workflow Clarity

Clear sequence with explicit validation checkpoints: Phase 0 tool-parameter verification before any first call, identifier resolution before any path, PATH 0 (OpenTargets) always first, retry/fallback chains with 'NEVER silently skip failed tools', a mandatory Completeness Audit checklist ('REQUIRED before finalizing'), and a final synthesis framework. These are feedback loops and a checklist exactly matching the top anchor.

Progressive Disclosure

The body is structured as a clean one-level-deep overview with a well-signaled reference table (IMPLEMENTATION.md, EVIDENCE_GRADING.md, REPORT_FORMAT.md, REFERENCE.md, EXAMPLES.md), which matches good disclosure design. However, scored against the actual bundle: no ./references/, ./scripts/, or ./assets/ directories exist and none of the five referenced files are present, so every reference in the body is dangling and the navigation the skill depends on does not resolve.

Specificity

The description enumerates five concrete capability areas, each tied to named data sources: 'tissue expression (GTEx, HPA), pathways, protein interactions (STRING), variant landscape (ClinVar, gnomAD), druggability (DGIdb, ChEMBL approved drugs)', plus the working method ('9 parallel research paths with citations'). This is comprehensive, concrete coverage with no vague filler — it fits the top anchor and exceeds anchor 4's 'minor gaps' level.

Completeness

Both questions are answered explicitly: 'what' is the first sentence plus the per-source capability list, and 'when' is a dedicated 'Use for full target profile reports, target characterization for drug discovery, and 'tell me about target X' queries' clause with concrete trigger phrases — matching the top anchor. It is not anchor 4, because the 'when' clause is already as explicit and specific as the 5-anchor example.

Trigger Term Quality

Good natural-phrase coverage: 'full target profile reports', 'target characterization for drug discovery', and especially the verbatim user phrasing "'tell me about target X' queries". A few natural synonyms users would plausibly say are missing — e.g., 'target validation', 'what do we know about [target]', 'drug target assessment' — which keeps it below anchor 5's comprehensive-synonym coverage (compare the '.pdf / PDFs / PDF files' example).

Distinctiveness Conflict Risk

A clear, well-defined niche (drug-target intelligence for drug discovery) with named source databases (GTEx, HPA, STRING, ClinVar, gnomAD, DGIdb, ChEMBL) and trigger phrasing ('target X', 'target profile reports') that is unlikely to fire for adjacent skills. This matches the 'clear niche with distinct triggers; minimal conflict risk' anchor.